Del Medtech Emerges: Steven Mickelsen, MD, Spearheads Expansion of Pulsed Field Ablation Beyond Cardiac Applications
MINNEAPOLIS, MN – September 4, 2025 – A significant stride in the field of medical technology has been announced with the launch of Del Medtech, a new venture founded by renowned electrophysiologist Dr. Steven Mickelsen. This innovative company is poised to significantly broaden the therapeutic applications of Pulsed Field Ablation (PFA), a groundbreaking energy modality currently making waves in cardiac procedures. Del Medtech aims to leverage the unique benefits of PFA to address a wider range of unmet medical needs outside of the heart.
Dr. Mickelsen, a distinguished figure known for his pioneering work in cardiac electrophysiology and catheter ablation, brings a wealth of experience and a deep understanding of PFA’s potential to Del Medtech. His vision is to unlock the non-thermal, tissue-selective nature of PFA for a variety of non-cardiac applications, potentially revolutionizing treatment for numerous conditions.
Pulsed Field Ablation represents a paradigm shift in tissue ablation. Unlike traditional thermal ablation methods, which rely on heat to destroy unwanted tissue, PFA utilizes short, high-energy electrical pulses. This non-thermal mechanism offers distinct advantages, including minimized damage to surrounding healthy tissues and reduced risk of thermal injury to critical structures, such as nerves and blood vessels. These characteristics are particularly attractive for treating delicate or complex anatomical regions.
While PFA has already demonstrated remarkable success and safety in treating cardiac arrhythmias, Del Medtech’s mission signifies a bold step towards exploring its therapeutic capabilities in other organ systems and disease states. The company is expected to focus on developing innovative PFA-based solutions for conditions that currently have limited or suboptimal treatment options.
“We are incredibly excited to embark on this journey with Del Medtech,” stated Dr. Steven Mickelsen. “The success of Pulsed Field Ablation in the cardiac arena has been truly inspiring, and we firmly believe its potential extends far beyond the heart. Our goal is to meticulously explore and develop PFA technologies that can offer safer, more effective, and less invasive treatment options for patients suffering from a variety of conditions.”
The establishment of Del Medtech signals a commitment to rigorous research, development, and clinical validation. The company is expected to collaborate with leading medical institutions and researchers worldwide to accelerate the translation of PFA technology into clinical practice for its expanded applications. This strategic approach aims to ensure that the development of new PFA-based therapies is guided by a strong foundation of scientific evidence and patient-centric innovation.
The expansion of PFA beyond cardiac procedures holds considerable promise. Potential applications could include the treatment of various types of tumors, management of chronic pain conditions, or addressing other tissue-specific pathologies where precise, non-thermal ablation is paramount. By focusing on these areas, Del Medtech aims to address significant unmet clinical needs and improve patient outcomes.
The launch of Del Medtech by Dr. Steven Mickelsen marks a pivotal moment in the evolution of medical technology. The company’s dedication to harnessing the power of Pulsed Field Ablation for broader therapeutic applications is anticipated to bring about significant advancements in patient care and treatment efficacy across a range of medical disciplines. Further developments from Del Medtech are eagerly awaited by the medical community.
Steven Mickelsen, MD, Launches Del Medtech to Expand Pulsed Field Ablation Beyond the Heart
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Steven Mickelsen, MD, Launches Del Medtech to Expand Pulsed Field Ablation Beyond the Heart’ at 2025-09-04 18:35. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.